Healthcare Industry News: lopinavir/ritonavir

Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV

Source: Gilead Sciences

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.